肝硬化

de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII: renewing consensus in portal hypertension. J Hepatol. 2022 Apr;76(4):959-74.全文  摘要

National Institute for Health and Care Excellence. Cirrhosis in over 16s: assessment and management. July 2016 [internet publication].全文

European Association for the Study of the Liver. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis: 2021 update. J Hepatol. 2021 Sep;75(3):659-89.全文  摘要

European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Aug;69(2):406-60.全文  摘要

Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management - 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017 Jan;65(1):310-35.全文  摘要

Rogal SS, Hansen L, Patel A, et al. AASLD practice guidance: palliative care and symptom-based management in decompensated cirrhosis. Hepatology. 2022 Sep;76(3):819-53.全文  摘要

1. Anthony PP, Ishak KG, Nayak NC, et al. The morphology of cirrhosis: definition, nomenclature, and classification. Bull World Health Organ. 1977;55(4):521-40. 摘要

2. Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020 Nov;18(12):2650-66.全文  摘要

3. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-66.全文  摘要

4. Hirode G, Saab S, Wong RJ. Trends in the burden of chronic liver disease among hospitalized US adults. JAMA Netw Open. 2020 Apr 1;3(4):e201997.全文  摘要

5. Office for Health Improvement and Disparities. Liver disease: applying All Our Health. May 2022 [internet publication].全文

6. Davis GL, Roberts WL. The healthcare burden imposed by liver disease in aging Baby Boomers. Curr Gastroenterol Rep. 2010 Feb;12(1):1-6. 摘要

7. Harris R, Card TR, Delahooke T, et al. Obesity is the most common risk factor for chronic liver disease: results from a risk stratification pathway using transient elastography. Am J Gastroenterol. 2019 Nov;114(11):1744-52. 摘要

8. Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ. 2018 Jul 18;362:k2817.全文  摘要

9. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012 Sep;57(3):675-88.全文  摘要

10. Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018 Sep;69(3):718-35. 摘要

11. Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019 Feb;65:37-55. 摘要

12. Lai JC, Rahimi RS, Verna EC, et al. Frailty associated with waitlist mortality independent of ascites and hepatic encephalopathy in a multicenter study. Gastroenterology. 2019 May;156(6):1675-82. 摘要

13. Chang KV, Chen JD, Wu WT, et al. Association of loss of muscle mass with mortality in liver cirrhosis without or before liver transplantation: A systematic review and meta-analysis. Medicine (Baltimore). 2019 Mar;98(9):e14373.全文  摘要

14. Dasarathy S. Cause and management of muscle wasting in chronic liver disease. Curr Opin Gastroenterol. 2016 May;32(3):159-65.全文  摘要

15. Alvarez MA, Cirera I, Solà R, et al. Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients. J Clin Gastroenterol. 2011 Nov-Dec;45(10):906-11. 摘要

16. D'Ambrosio R, Aghemo A, Rumi MG, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012 Aug;56(2):532-43. 摘要

17. Pellicoro A, Aucott RL, Ramachandran P, et al. Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis. Hepatology. 2012 Jun;55(6):1965-75. 摘要

18. Govaere O, Roskams T. Pathogenesis and prognosis of hepatocellular carcinoma at the cellular and molecular levels. Clin Liver Dis. 2015 May;19(2):261-76. 摘要

19. Ortega-Alonso A, Andrade RJ. Chronic liver injury induced by drugs and toxins. J Dig Dis. 2018 Sep;19(9):514-21. 摘要

20. Andrade RJ, Medina-Caliz I, Gonzalez-Jimenez A, et al. Hepatic damage by natural remedies. Semin Liver Dis. 2018 Feb;38(1):21-40.全文  摘要

21. Ahmed Z, Ahmed U, Walayat S, et al. Liver function tests in identifying patients with liver disease. Clin Exp Gastroenterol. 2018 Aug 23;11:301-7.全文  摘要

22. Sullivan MK, Daher HB, Rockey DC. Normal or near normal aminotransferase levels in patients with alcoholic cirrhosis. Am J Med Sci. 2022 Jun;363(6):484-9. 摘要

23. Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. 2003 Jan 27;163(2):218-24.全文  摘要

24. Cai JJ, Wang K, Jiang HQ, et al. Characteristics, risk factors, and adverse outcomes of hyperkalemia in acute-on-chronic liver failure patients. Biomed Res Int. 2019 Feb 27;2019:6025726.全文  摘要

25. Wallerstedt S, Simrén M, Wahlin S, et al. Moderate hyperkalemia in hospitalized patients with cirrhotic ascites indicates a poor prognosis. Scand J Gastroenterol. 2013 Mar;48(3):358-65.全文  摘要

26. O'Shea RS, Davitkov P, Ko CW, et al. AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis. Gastroenterology. 2021 Nov;161(5):1615-27.全文  摘要

27. Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008 Jun;48(6):1000-7.全文  摘要

28. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017 Jan;112(1):18-35.全文  摘要

29. European Association for the Study of the Liver. EASL clinical practice guidelines on haemochromatosis. J Hepatol. 2022 Aug;77(2):479-502.全文  摘要

30. Liu WT, Jing YY, Han ZP, et al. The injured liver induces hyperimmunoglobulinemia by failing to dispose of antigens and endotoxins in the portal system. PLoS One. 2015;10(3):e0122739.全文  摘要

31. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003 Oct 1;168(7):818-900.全文  摘要

32. Zhang J, Chen G, Zhang P, et al. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2020 Feb 13;15(2):e0228857.全文  摘要

33. de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII: renewing consensus in portal hypertension. J Hepatol. 2022 Apr;76(4):959-74.全文  摘要

34. Wickremeratne T, Turner S, O'Beirne J. Systematic review with meta-analysis: ultra-thin gastroscopy compared to conventional gastroscopy for the diagnosis of oesophageal varices in people with cirrhosis. Aliment Pharmacol Ther. 2019 Jun;49(12):1464-73. 摘要

35. National Institute for Health and Care Excellence. Cirrhosis in over 16s: assessment and management. July 2016 [internet publication].全文

36. Vadera S, Yong CWK, Gluud LL, et al. Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices. Cochrane Database Syst Rev. 2019 Jun 20;6:CD012673.全文  摘要

37. Roccarina D, Best LM, Freeman SC, et al. Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev. 2021 Apr 6;4(4):CD013121.全文  摘要

38. Deng H, Qi X, Guo X. Computed tomography for the diagnosis of varices in liver cirrhosis: a systematic review and meta-analysis of observational studies. Postgrad Med. 2017 Apr;129(3):318-28. 摘要

39. Xiao H, Shi M, Xie Y, et al. Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: a systematic review and meta-analysis. PLoS One. 2017 Nov 6;12(11):e0186660.全文  摘要

40. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182-236. 摘要

41. West J, Card TR. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology. 2010 Oct;139(4):1230-7. 摘要

42. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1-85. 摘要

43. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646-9. 摘要

44. Jepsen P, Vilstrup H, Lash TL. Development and validation of a comorbidity scoring system for patients with cirrhosis. Gastroenterology. 2014 Jan;146(1):147-56; quiz e15-6. 摘要

45. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008 Sep 4;359(10):1018-26.全文  摘要

46. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 Feb;33(2):464-70. 摘要

47. Barr RG, Wilson SR, Rubens D, et al. Update to the Society of Radiologists in Ultrasound liver elastography consensus statement. Radiology. 2020 Aug;296(2):263-74.全文  摘要

48. Talwalkar JA, Kurtz DM, Schoenleber SJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1214-20. 摘要

49. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008 Apr;134(4):960-74. 摘要

50. Stebbing J, Farouk L, Panos G, et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol. 2010 Mar;44(3):214-9. 摘要

51. Chon YE, Choi EH, Song KJ, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One. 2012;7(9):e44930.全文  摘要

52. Takuma Y, Nouso K, Morimoto Y, et al. Measurement of spleen stiffness by acoustic radiation force impulse imaging identifies cirrhotic patients with esophageal varices. Gastroenterology. 2013 Jan;144(1):92-101.e2.全文  摘要

53. Cassinotto C, Boursier J, de Lédinghen V, et al. Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology. 2016 Jun;63(6):1817-27. 摘要

54. Hu X, Qiu L, Liu D, et al. Acoustic radiation force impulse (ARFI) elastography for non‑invasive evaluation of hepatic fibrosis in chronic hepatitis B and C patients: a systematic review and meta-analysis. Med Ultrason. 2017 Jan 31;19(1):23-31.全文  摘要

55. Adebajo CO, Talwalkar JA, Poterucha JJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2012 Mar;18(3):323-31.全文  摘要

56. European Association for the Study of the Liver. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis: 2021 update. J Hepatol. 2021 Sep;75(3):659-89.全文  摘要

57. Yang D, Li D, Li J, et al. Systematic review: the diagnostic efficacy of gadoxetic acid-enhanced MRI for liver fibrosis staging. Eur J Radiol. 2020 Apr;125:108857. 摘要

58. de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52.全文  摘要

59. European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Aug;69(2):406-60.全文  摘要

60. Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015 Apr;64(4):531-7.全文  摘要

61. Flamm SL, Wong F, Ahn J, et al. AGA clinical practice update on the evaluation and management of acute kidney injury in patients with cirrhosis: expert review. Clin Gastroenterol Hepatol. 2022 Dec;20(12):2707-16.全文  摘要

62. Wong F. Acute kidney injury in liver cirrhosis: new definition and application. Clin Mol Hepatol. 2016 Dec;22(4):415-22.全文  摘要

63. Perumpail BJ, Li AA, Cholankeril G, et al. Optimizing the nutritional support of adult patients in the setting of cirrhosis. Nutrients. 2017 Oct 13;9(10):E1114.全文  摘要

64. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. Hepatitis C guidance 2023 update: recommendations for testing, managing, and treating hepatitis C virus infection. Oct 2023 [internet publication].全文

65. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-98.全文  摘要

66. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-99.全文  摘要

67. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417.全文  摘要

68. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021 Jan;70(1):9-29.全文  摘要

69. Wong CL, Holroyd-Leduc J, Thorpe KE, et al. Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results? JAMA. 2008 Mar 12;299(10):1166-78.全文  摘要

70. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000;32(1):142-53. 摘要

71. Bernardi M, Carceni P, Navickis RJ, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012 Apr;55(4):1172-81.全文  摘要

72. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021 Jan;70(1):9-29.全文  摘要

73. Bernardi M, Caraceni P, Navickis RJ, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012 Apr;55(4):1172-81. 摘要

74. Benmassaoud A, Freeman SC, Roccarina D, et al. Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev. 2020 Jan 16;1:CD013123.全文  摘要

75. D'Amico G, Luca A, Morabito A, et al. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology. 2005 Oct;129(4):1282-93. 摘要

76. Saab S, Nieto JM, Lewis SK, et al. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004889.全文  摘要

77. Albillos A, Bañares R, González M, et al. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol. 2005 Dec;43(6):990-6. 摘要

78. Salerno F, Cammà C, Enea M, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology. 2007 Sep;133(3):825-34.全文  摘要

79. Chen RP, Zhu Ge XJ, Huang ZM, et al. Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites: metaregression and trial sequential meta-analysis. J Clin Gastroenterol. 2014 Mar;48(3):290-9. 摘要

80. Bai M, Qi XS, Yang ZP, et al. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol. 2014 Mar 14;20(10):2704-14.全文  摘要

81. Lebrec D, Giuily N, Hadengue A, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol. 1996 Aug;25(2):135-44. 摘要

82. Macken L, Joshi D, Messenger J, et al. Palliative long-term abdominal drains in refractory ascites due to end-stage liver disease: a case series. Palliat Med. 2017 Jul;31(7):671-5. 摘要

83. Dahl E, Gluud LL, Kimer N, et al. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. Aliment Pharmacol Ther. 2012 Oct;36(7):619-26. 摘要

84. Yan L, Xie F, Lu J, et al. The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials. BMC Gastroenterol. 2015 Jun 9;15:65.全文  摘要

85. Tripathi D, Stanley AJ, Hayes PC, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015 Nov;64(11):1680-704.全文  摘要

86. Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management - 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017 Jan;65(1):310-35.全文  摘要

87. Kerbert AJ, Chiang FW, van der Werf M, et al. Hemodynamic response to primary prophylactic therapy with nonselective beta-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis: a meta-analysis. Eur J Gastroenterol Hepatol. 2017 Apr;29(4):380-7. 摘要

88. Bossen L, Krag A, Vilstrup H, et al. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients. Hepatology. 2016 Jun;63(6):1968-76. 摘要

89. Sinha R, Lockman KA, Mallawaarachchi N, et al. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. J Hepatol. 2017 Jul;67(1):40-46. 摘要

90. Leithead JA, Rajoriya N, Tehami N, et al. Non-selective beta-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut. 2015 Jul;64(7):1111-9. 摘要

91. Zacharias AP, Jeyaraj R, Hobolth L, et al. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev. 2018 Oct 29;10:CD011510.全文  摘要

92. Garcia-Pagán JC, Bosch J. Endoscopic band ligation in the treatment of portal hypertension. Nat Clin Pract Gastroenterol Hepatol. 2005 Nov;2(11):526-35. 摘要

93. Li L, Yu C, Li Y. Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis. Can J Gastroenterol. 2011 Mar;25(3):147-55.全文  摘要

94. Yan K, Bridges JF, Augustin S, et al. Factors impacting physicians' decisions to prevent variceal hemorrhage. BMC Gastroenterol. 2015 May 2;15:55.全文  摘要

95. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology. 1995 Jul;22(1):332-54.全文  摘要

96. Vine LJ, Subhani M, Acevedo JG. Update on management of gastric varices. World J Hepatol. 2019 Mar 27;11(3):250-60.全文  摘要

97. Odutayo A, Desborough MJ, Trivella M, et al. Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials. Lancet Gastroenterol Hepatol. 2017 May;2(5):354-60. 摘要

98. Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the international consensus group. Ann Intern Med. 2019 Dec 3;171(11):805-22. 摘要

99. Lau JYW, Yu Y, Tang RSY, et al. Timing of endoscopy for acute upper gastrointestinal bleeding. N Engl J Med. 2020 Apr 2;382(14):1299-308.全文  摘要

100. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010 Sep 8;(9):CD002907.全文  摘要

101. Fernández J, Ruiz del Arbol L, Gómez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 2006 Oct;131(4):1049-56.全文  摘要

102. Tandon P, Abraldes JG, Keough A, et al. Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on Child-Pugh class, and effects of antibiotics. Clin Gastroenterol Hepatol. 2015 Jun;13(6):1189-96.全文  摘要

103. Maiwall R, Jamwal KD, Bhardwaj A, et al. SX-Ella Stent Danis effectively controls refractory variceal bleed in patients with acute-on-chronic liver failure. Dig Dis Sci. 2018 Feb;63(2):493-501. 摘要

104. Lai JC, Tandon P, Bernal W, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Sep;74(3):1611-44.全文  摘要

105. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999 Aug 5;341(6):403-9.全文  摘要

106. Loomba R, Wesley R, Bain A, et al. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol. 2009 Apr;7(4):487-93. 摘要

107. Kamal F, Khan MA, Khan Z, et al. Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017 Oct;29(10):1109-17. 摘要

108. Iogna Prat L, Wilson P, Freeman SC, et al. Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev. 2019 Sep 16;9:CD013120.全文  摘要

109. Badillo R, Rockey DC. Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature. Medicine (Baltimore). 2014 May;93(3):135-42.全文  摘要

110. Baig MA, Majeed MB, Attar BM, et al. Efficacy and safety of indwelling pleural catheters in management of hepatic hydrothorax: a systematic review of literature. Cureus. 2018 Aug 6;10(8):e3110.全文  摘要

111. Xiol X, Tremosa G, Castellote J, et al. Liver transplantation in patients with hepatic hydrothorax. Transpl Int. 2005 Jun;18(6):672-5.全文  摘要

112. Jepsen P, Ott P, Andersen PK, et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010 May;51(5):1675-82.全文  摘要

113. Sharma BC, Sharma P, Agrawal A, et al. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009 Sep;137(3):885-91, 891.e1.全文  摘要

114. Shi D, Zhou Z, Dai Y, et al. Proton pump inhibitor therapy and hepatic encephalopathy risk in cirrhotic patients: a systematic review with meta-analysis. Clin Drug Investig. 2019 Sep;39(9):847-56. 摘要

115. Tantai XX, Yang LB, Wei ZC, et al. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: a meta-analysis. World J Gastroenterol. 2019 Jun 7;25(21):2683-98.全文  摘要

116. Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013 Sep;108(9):1458-63. 摘要

117. Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016 May 6;(5):CD003044.全文  摘要

118. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 Aug;60(2):715-35. 摘要

119. Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology. 2015 Aug;62(2):567-74.全文  摘要

120. Lim AKH, Crnobrnja L, Metlapalli M, et al. Observational study of the relative efficacy of insulin-glucose treatment for hyperkalaemia in patients with liver cirrhosis. BMJ Open. 2021 Oct 22;11(10):e051201.全文  摘要

121. Rodríguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome - a liver-induced lung vascular disorder. N Engl J Med. 2008 May 29;358(22):2378-87. 摘要

122. Grilo-Bensusan I, Pascasio-Acevedo JM. Hepatopulmonary syndrome: what we know and what we would like to know. World J Gastroenterol. 2016 Jul 7;22(25):5728-41.全文  摘要

123. Sitbon O, Bosch J, Cottreel E, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019 Jul;7(7):594-604. 摘要

124. Bajaj JS, O'Leary JG, Lai JC, et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol. 2022 Feb 1;117(2):225-52.全文  摘要

125. Nanchal R, Subramanian R, Karvellas CJ, et al. Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: cardiovascular, endocrine, hematologic, pulmonary, and renal considerations. Crit Care Med. 2020 Mar;48(3):e173-91.全文  摘要

126. United Network for Organ Sharing. Transplant trends. 2022 [internet publication].全文

127. Tandon P, Walling A, Patton H, et al. AGA clinical practice update on palliative care management in cirrhosis: expert review. Clin Gastroenterol Hepatol. 2021 Apr;19(4):646-56.全文  摘要

128. Rogal SS, Hansen L, Patel A, et al. AASLD practice guidance: palliative care and symptom-based management in decompensated cirrhosis. Hepatology. 2022 Sep;76(3):819-53.全文  摘要

129. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Aug;74(2):1014-48.全文  摘要

130. Borrello MT, Mann D. Chronic liver diseases: from development to novel pharmacological therapies - IUPHAR review 37. Br J Pharmacol. 2022 Apr 7 [Epub ahead of print].全文  摘要

131. Lebrec D, Thabut D, Oberti F, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology. 2010;138:1755-1762. 摘要

132. Stine JG, Wang J, Cornella SL, et al. Treatment of type-1 hepatorenal syndrome with pentoxifylline: a randomized placebo controlled clinical trial. Ann Hepatol. 2018 Mar 1;17(2):300-6.全文  摘要

133. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006 Jan;44(1):217-31. 摘要

134. Pinter M, Trauner M, Peck-Radosavljevic M, et al. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1(2):e000042.全文  摘要

135. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-80.全文  摘要

136. Segarra-Newnham M, Henneman A. Antibiotic prophylaxis for prevention of spontaneous bacterial peritonitis in patients without gastrointestinal bleeding. Ann Pharmacother. 2010 Dec;44(12):1946-54. 摘要

137. Bureau C, Thabut D, Jezequel C, et al. The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial. Ann Intern Med. 2021 May;174(5):633-40. 摘要

138. Gifford FJ, Morling JR, Fallowfield JA. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Aliment Pharmacol Ther. 2017 Mar;45(5):593-603.全文  摘要

139. Saab S. Current treatment of thrombocytopenia in chronic liver disease. Gastroenterol Hepatol (N Y). 2019 Oct;15(10):558-60.全文  摘要

140. O'Leary JG, Greenberg CS, Patton HM, et al. AGA clinical practice update: coagulation in cirrhosis. Gastroenterology. 2019 Jul;157(1):34-43.e1. 摘要

141. Nadarevic T, Giljaca V, Colli A, et al. Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev. 2021 Oct 6;10(10):CD013362.全文  摘要

142. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006 Oct;55 Suppl 6:vi1-12.全文  摘要

143. Brustia R, Savier E, Scatton O. Physical exercise in cirrhotic patients: towards prehabilitation on waiting list for liver transplantation. A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2018 Jun;42(3):205-15. 摘要

144. Locklear CT, Golabi P, Gerber L, et al. Exercise as an intervention for patients with end-stage liver disease: systematic review. Medicine (Baltimore). 2018 Oct;97(42):e12774.全文  摘要

145. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices recommended adult immunization schedule for ages 19 years or older - United States, 2023. Feb 2023 [internet publication].全文

146. Villanueva C, Albillos A, Genescà J, et al. Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019 Apr 20;393(10181):1597-608. 摘要